Evidence map›Paper›PMID 42564338›Full record

ArticleInternational journal of vascular medicine2026

Midterm Outcomes of Endovascular-First Revascularization for Multilevel Peripheral Arterial Disease With Chronic Limb-Threatening Ischemia: A Retrospective Study From Vietnam.

Lam Van Nut, Trinh Vu Nghia

Abstract read
In one paragraph

Article in International journal of vascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lam Van NutDepartment of Vascular Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam, choray.vn.ORCID https://orcid.org/0009-0008-8189-4785
Trinh Vu NghiaDepartment of Vascular Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam, choray.vn.ORCID https://orcid.org/0009-0002-3778-1405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Peripheral arterial disease (PAD) with chronic limb-threatening ischemia (CLTI) represents advanced systemic atherosclerosis and carries high risks of amputation and mortality. Multilevel arterial involvement is common and often requires revascularization of both inflow and outflow segments. However, midterm outcome data in Vietnam remain limited. Objectives: This study is aimed at evaluating midterm clinical outcomes and identifying factors associated with wound healing, all-cause mortality, and major limb amputation after an endovascular-first revascularization strategy for multilevel PAD with CLTI. Methods: This retrospective case series included 91 patients with multilevel PAD (≥ 2 anatomical levels according to TASC II) and CLTI (Rutherford 4-6) treated at a tertiary hospital in Vietnam from 2017 to 2019. Patients were followed for 24 months. Kaplan-Meier analysis was used to describe survival, limb salvage, and wound healing over 24 months. Univariable and multivariable logistic regressions were used to identify factors associated with fixed-time binary outcomes within 24 months, including wound healing, mortality, and major limb amputation. Results: The mean age was 74.0 ± 11.6 years, and 82.4% were male. The ankle-brachial index improved significantly after intervention (0.2 vs. 0.5; Conclusion: An endovascular-first revascularization strategy for multilevel PAD with CLTI achieved acceptable midterm limb salvage and wound healing, although mortality remained considerable. Risk stratification and multimodal care are essential to improve outcomes.

Indexed as

chronic limb-threatening ischemiaendovascularmultilevel peripheral arterial diseaserevascularization

Identifiers

PMID42564338
PMCPMC13442587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.